Omalizumab (Xolair) in Children Above 12 Years With Chronic Urticaria: A Review of Literature
Generally, 15-25% of general population experience urticaria during their life. The prevalence of chronic urticaria is about 0.1-0.3% in children and most often occurs between ages of 6-11 years. There are several causes for development of chronic urticaria. Known etiologies of chronic urticaria in...
Main Authors: | Javad Ghaffari, Soheila Shahmohammadi, Hossein Ashrafi, Ali Reza Ranjbar, Negar Ghaffari |
---|---|
Format: | Article |
Language: | English |
Published: |
Mazandaran University of Medical Sciences
2015-01-01
|
Series: | Journal of Pediatrics Review |
Subjects: | |
Online Access: | http://jpr.mazums.ac.ir/browse.php?a_code=A-10-28-8&slc_lang=en&sid=1 |
Similar Items
-
Omalizumab (Xolair) in Children with Atopic Dermatitis: A Review Article
by: Javad Ghaffari, et al.
Published: (2018-01-01) -
Omalizumab for treatment of chronic urticaria: A review of effective dose
by: javad Ghaffari, et al.
Published: (2019-03-01) -
Safety of Methotrexate in Chronic Urticaria Unresponsive to Omalizumab
by: Mehmet Unsel
Published: (2021-08-01) -
Position of omalizumab therapy in the treatment of spontaneous chronic urticaria. A case series and literature review
by: Aleksander Obtułowicz, et al.
Published: (2022-05-01) -
The use of an urticaria control test for the evaluation of omalizumab treatment response in patients diagnosed with chronic urticaria
by: Burhan Engin, et al.
Published: (2020-12-01)